07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Carbylan BioSurgery board of directors update

Carbylan BioSurgery Inc. , Palo Alto, Calif.   Business: Inflammation, Autoimmune   Appointed: Samuel Lynch as chairman; Lynch founded BioMimetic Therapeutics Inc. , which Wright Medical Group Inc. acquired  ...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Carbylan BioSurgery management update

Carbylan BioSurgery Inc. , Palo Alto, Calif.   Business: Inflammation, Autoimmune   Hired: David Renzi as president, CEO and a director, formerly president and CEO of Neomend Inc., which C.R. Bard Inc. acquired  ...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Carbylan BioSurgery, Shanghai Jingfeng deal

Carbylan granted Shanghai Jingfeng exclusive Chinese rights to undisclosed patents and IP related to Carbylan's Hydros-TA technology. Carbylan received an undisclosed upfront payment and is eligible for development, regulatory and commercialization milestones. Shanghai Jingfeng will...
07:00 , Aug 1, 2011 |  BC Week In Review  |  Clinical News

Hydros-TA: Phase II data

In the double-blind, international Phase II COR1.0 trial in 98 patients with osteoarthritis of the knee, Carbylan said a single intra-articular injection of Hydros or Hydros-TA had "positive results" in pain and function scores and...